Janssen Pharmaceuticals' ulcerative colitis drug induces clinical remission — 5 insights

A single dose of Janssen Pharmaceuticals' Stelara induced clinical remission in patients with moderate to severe ulcerative colitis, according to data presented at the ACG 2018, Oct. 5-10 in Philadelphia.

Here's what you should know:

1. Researchers conducted a phase 3 study examining the effects of a single intravenous dose of Stelara.

2. About 961 patients were enrolled in the study, receiving either a single IV dose of a placebo, 130 mg of Stelara or around 6 mg/kg of Stelara, depending on their weight.

3. About 15.6 percent of the 130 mg patients and 15.5 percent of the weight-based patients achieved clinical remission.

4. About 26.3 percent of the 130 mg patients and 27 percent of the weight-based patients experienced endoscopic healing.

5. Both Stelara dosage groups made statistically significant improvements in the Inflammatory Bowel Disease Questionnaire.

Janssen Research and Development Vice President of Clinical Development Philippe Szapary, MD, said, "These induction data from the [phase 3] study underscore the potential for this pathway in the treatment of UC, which may lead to a new effective and safe treatment option for UC patients in the future."

More articles on gastroenterology:
North Carolina finalizes plan that could spur ASC, hospital developments — 5 takeaways
Envision Healthcare (AmSurg) fights back on false billing claims & more — 8 ASC company key notes
114 ASC benchmarks to know | 2018

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers